RNA-Based Oncolytic Therapy Market 2026 gaining traction in precision oncology

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Over The 2026–2030 Period?

The ribonucleic acid (rna)-based oncolytic therapy market size has experienced rapid growth in recent years. It is anticipated to expand from $2.12 billion in 2025 to $2.51 billion by 2026, reflecting a compound annual growth rate (CAGR) of 18.7%. This historic growth can be attributed to advancements in cancer virology research, a growing understanding of tumor immunology, the presence of clinical trial infrastructure, increasing oncology research funding, and the early success demonstrated by oncolytic virus studies.

The ribonucleic acid (rna)-based oncolytic therapy market is poised for significant expansion in the coming years. Its value is projected to reach $4.94 billion by 2030, advancing at a compound annual growth rate (CAGR) of 18.4%. This anticipated growth is driven by factors such as the increasing approvals for rna-based cancer treatments, a growing need for personalized oncology solutions, the broadening of immuno-oncology pipelines, rising investments in gene and cell therapies, and technological enhancements in rna delivery systems. Prominent trends expected during this forecast period include further advancements in rna virus engineering, increased adoption of combination oncolytic therapies, a heightened focus on immune system activation, the expansion of targeted tumor-specific rna therapies, and better integration of precision oncology tools.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28321&type=smp

Which Major Factors Are Driving The Expansion Of The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?

The RNA-based oncolytic therapy market is projected to grow due to the increasing adoption of personalized medicine. Personalized medicine refers to medical treatments specifically designed based on an individual’s genetic profile, which leads to improved effectiveness and fewer adverse reactions. The uptake of personalized medicine is expanding as more healthcare providers and institutions acknowledge its capacity to enhance patient outcomes through targeted therapies and precise diagnostic methods. RNA-based oncolytic therapy plays a vital role in cancer care by aligning with the growing trend of personalized medicine to offer targeted and patient-specific treatment strategies. For instance, in February 2024, the Personalized Medicine Coalition, a US-based advocacy group for tailored medical treatments, noted that the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from 6 in 2022. Consequently, the rising adoption of personalized medicine is a key driver for the RNA-based oncolytic therapy market.

How Is The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Segmented Across Key Categories?

The ribonucleic acid (rna)-based oncolytic therapy market covered in this report is segmented –

1) By Therapy Type: Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy, Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy, Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy, Other Therapy Types

2) By Route Of Administration: Intravenous, Intratumoral, Other Route Of Administrations

3) By Application: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Other Applications

4) By End-User: Hospitals, Cancer Research Institutes, Specialty Clinics, Other End-Users

Subsegments:

1) By Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy: Self-Amplifying mRNA (saRNA), Non-Replicating mRNA, Circular RNA (circRNA)-Based mRNA therapy

2) By Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy: Chemically Modified siRNA, Nanoparticle-Delivered siRNA, Conjugated siRNA

3) By Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy: miRNA Mimics, miRNA Inhibitors (Antagomirs), miRNA Aponges Or Decoys

4) By Other Therapy Types: Long Non-Coding RNA (lncRNA)-Based Therapies, Short Hairpin RNA (shRNA)-Based Therapies, Aptamer-RNA Based Oncolytic Agents

Which Upcoming Trends Are Expected To Influence The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?

Leading companies in the ribonucleic acid (RNA)-based oncolytic therapy market are concentrating on advancing technologies like synthetic messenger RNA (mRNA) technology to boost tumor-targeting efficiency, enhance immune activation, and deliver more precise and lasting cancer treatment results. Synthetic messenger RNA (mRNA) technology represents a biotechnology strategy that involves designing and introducing lab-created mRNA sequences to direct cells to generate specific therapeutic proteins for disease management, including cancer. For example, in June 2024, CSPC Pharmaceutical Group Limited, a pharmaceutical enterprise headquartered in China, obtained regulatory approval in China to begin clinical trials for SYS6020, its synthetic mRNA-based cancer cell therapy. This progress signifies a significant step forward in China’s messenger RNA therapeutics sector. SYS6020 leverages mRNA-lipid nanoparticle technology to specifically pinpoint and remove myeloma cancer cells with few side effects, simultaneously showing potential applicability in managing certain autoimmune diseases.

Who Are The Dominant Players Shaping The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Landscape?

Major companies operating in the ribonucleic acid (rna)-based oncolytic therapy market are AstraZeneca PLC, Moderna Inc., BioNTech SE, Gritstone Bio Inc., Orna Therapeutics Inc., Strand Therapeutics Inc., Oncolytics Biotech Inc., Anima Biotech Inc., eTheRNA immunotherapies NV, Vyriad Inc., Haya Therapeutics Inc., Virogin Biotech Inc., Providence Therapeutics Holdings Inc., Sirnaomics Inc., Humane Genomics Inc., Replicate Bioscience Inc., Abogen Biosciences Inc., Chimeron Bio Inc., Aro Biotherapeutics Inc., TransCode Therapeutics Inc.

Read the full ribonucleic acid (rna)-based oncolytic therapy market report here:

https://www.thebusinessresearchcompany.com/report/ribonucleic-acid-rna-based-oncolytic-therapy-global-market-report

Which Region Currently Holds The Largest Share Of The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?

North America was the largest region in the ribonucleic acid (RNA)-based oncolytic therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (rna)-based oncolytic therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28321&type=smp

Browse Through More Reports Similar to the Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market 2026, By The Business Research Company

Ribose Nucleic Acid Rna Based Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/ribose-nucleic-acid-rna-based-therapeutics-global-market-report

Oncolytic Virus Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

Nucleic Acid Based Gene Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795